Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis | Zendy

David W. Dempster | Zendy; Jacques P. Brown | Zendy; Astrid FahrleitnerPammer | Zendy; David L. Kendler | Zendy; Sébastien Rizzo | Zendy; Ivo Valter | Zendy; Rachel B. Wagman | Zendy; Xiang Yin | Zendy; Susan Yue | Zendy; Georges Boivin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis

Author(s) -

David W. Dempster,

Jacques P. Brown,

Astrid FahrleitnerPammer,

David L. Kendler,

Sébastien Rizzo,

Ivo Valter,

Rachel B. Wagman,

Xiang Yin,

Susan Yue,

Georges Boivin

Publication year - 2018

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-02669

Subject(s) - denosumab , bone histomorphometry , osteoporosis , postmenopausal osteoporosis , medicine , mineralization (soil science) , postmenopausal women , bone density conservation agents , bone remodeling , bone formation , dentistry , trabecular bone , bone density , bone mineral , chemistry , organic chemistry , nitrogen

Denosumab is a potent antiresorptive agent that reduces fractures in postmenopausal women with osteoporosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research